drugset / Trial / NCT07715136
BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy
NaSequentialOpen-labelTreatment
Summary
This single-arm, open-label, phase I trial evaluates the safety and tolerability of ICG318 CAR-T (BCMA-CD19-IL-15/IL15sushi cCAR T cells) in patients with refractory Idiopathic inflammatory myopathy (IIM).
Timeline
- Start
- 2025-03-20
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ICG318 | Cell therapy | — | — |